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Abstract
Background Left ventricular assist devices (LVADs) are increasingly used for the treatment of advanced heart failure. LVADs
improve quality of life and decrease mortality, but the driveline carries substantial risk for major infections. These device-related
LVAD and driveline infections are difficult to diagnose with conventional imaging. We reviewed and analysed the current
literature on the additive value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography
(FDG-PET/CT) imaging for the diagnosis of LVAD-related infections.”
Materials/methods We performed a systematic literature review using several databases from their inception until the 31st of
December, 2019. Studies investigating the diagnostic performance of FDG-PET/CT in patients with suspected LVAD infection
were retrieved. After a bias risk assessment using QUADAS-2, a study-aggregate meta-analysis was performed on a per
examination-based analysis.
Results A total of 10 studies were included in the systematic review, eight of which were also eligible for study-aggregate meta-
analysis. For the meta-analysis, a total of 256 FDG-PET/CT scans, examining pump/pocket and/or driveline infection, were
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acquired in 230 patients. Pooled sensitivity of FDG-PET/CT was 0.95 (95% confidence interval (CI) 0.89–0.97) and pooled
specificity was 0.91 (95% CI 0.54–0.99) for the diagnosis of device-related infection. For pump/pocket infection, sensitivity and
specificity of FDG-PET/CT were 0.97 (95%CI 0.69–1.00) and 0.93 (95%CI 0.64–0.99), respectively. For driveline infection,
sensitivity and specificity were 0.96 (95%CI 0.88–0.99) and 0.99 (95%CI 0.13–1.00) respectively. Significant heterogeneity
existed across studies for specificity, mostly caused by differences in scan procedures. Predefined criteria for suspicion of LVAD
and/or driveline infection were lacking in all included studies.
Conclusions FDG-PET/CT is a valuable tool for assessment of device-related infection in LVAD patients, with high sensitivity
and high, albeit variable, specificity. Standardization of FDG-PET/CT procedures and criteria for suspected device-related
LVAD infections are needed for consistent reporting of FDG-PET/CT scans.
Keywords LVAD infection . 18F-FDGPET/CT . Systematic review .Meta-analysis
Abbreviations
BSAC British Society of Antimicrobial Chemotherapy
CF-LVAD Continuous-flow left ventricular assist device
CT Computed tomography
DOR Diagnostic odds ratio
EANM European Association of Nuclear Medicine
EARL EANM Research ltd
ESC European Society of Cardiology
FDG 18F-fluorodeoxyglucose
ISHLT International Society of Heart and Lung
Transplantation
ICD Implantable cardioverter defibrillator
LVAD Left ventricular assist device
NLR Negative likelihood ratio
NR Not reported
PET Positron emission tomography
PLR Positive likelihood ratio
P R I S M A -
DTA
Preferred reporting items for systematic reviews




Quality Assessment of Diagnostic Accuracy
Studies-version 2
SUVmax Maximum standardized uptake value
TBR Target-to-background ratio
VAD (any) ventricular assist device
Introduction
Left ventricular assist devices (LVADs) are an established
treatment option for end-stage heart failure, either as a
bridge-to-transplantation, bridge to decision or as destination
therapy. LVAD treatment is associated with improvement in
quality of life and improved survival. Already in 2001,
LVADs have been shown to improve 1-year survival from
25 to 50% compared with conservative medical treatment
[1]. With subsequent LVAD generations, outcomes have fur-
ther improved, with 4-year survival for LVAD recipients now
approaching that of heart transplantation (60% and 70%, re-
spectively) [2].
However, infection of either the driveline or the LVADpock-
et or pump itself still remains an important clinical problem. The
overall incidence has decreased over time, but infection still
occurs in 18.1% of patients during the first year after implanta-
tion and in 11.9% the years thereafter [2]. LVAD infections are
associated with significant morbidity and mortality [3], in par-
ticular when complicated by bloodstream infection, which has
an overall mortality rate of up to 50% [4, 5]. Establishing the
diagnosis accurately and at an early stage is essential for effec-
tive management and optimal patient outcome.
The diagnosis of device-related LVAD infections mainly
relies on clinical findings and results from microbiology
and imaging. Swabs taken at the driveline exit site and
blood cultures are a mainstay for the diagnosis, but they
provide no information about the extent of an infection.
Surgical removal and subsequent culture of the device is
the gold standard for diagnosis, but this is often not feasible
because of the severe risks associated with exchanging
these devices. Imaging techniques such as echocardiogra-
phy and CT angiography (CTA) are commonly used, but
their diagnostic accuracy is limited due to device-related
scatter artefacts, while LVAD components themselves
may mimic infectious complications e.g. appearance of par-
tially obstructed flow on echocardiography or blood be-
tween outflow graft and surrounding Gore-Tex mimicking
thrombus on contrast-enhanced CT [6, 7].
Mo l e c u l a r im a g i n g , a n d s p e c i f i c a l l y 1 8 F -
fluordeoxyglucose positron emission tomography (FDG-
PET) combined with low-dose or contrast-enhanced CT
(FDG-PET/CT), is increasingly used for assessment of
device-related infections. For endocarditis and infections in
patients with cardiac implantable electronic devices, i.e. pace-
makers, implantable cardioverter defibrillators (ICDs), FDG-
PET/CT has already been incorporated in ESC guidelines and
its diagnostic value for this indication is supported by an ex-
tensive body of evidence [8–11]. Its value for the diagnosis of
LVAD-related infections is still being investigated, but here
supporting evidence is also emerging.
The aim of this systematic review and meta-analysis is to
provide a detailed overview of all evidence so far to establish
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the role of FDG-PET/CT in diagnosing LVAD-related infec-
tions. For the analysis, a distinction was made between drive-
line infections and infections of the pump/pocket.
Research design and methods
Screening and selection of literature
This systematic review and meta-analysis was performed ac-
cording to the Cochrane methodology and PRISMA-DTA
statement [12]. A comprehensive literature search was per-
formed by two authors (DtH and GT) on PubMed, the
Cochrane Library database and Embase. The search included
the following terms: ‘Left Ventricular Assist Device’,
‘Infection’, ‘Driveline Infection’, ‘Endocarditis’”, and
‘Positron Emission Tomography’ or variations of these search
terms. For the exact search strings, we refer to the supplemen-
tal data. Studies published up to the 31st of December 2019
were used in our analyses. Original articles that evaluated the
diagnostic performance of FDG-PET/CT for suspicion of
LVAD infection were eligible for inclusion in the systematic
review. References in selected studies were cross-checked to
find other relevant articles. Both retrospective and prospective
studies as well as blinded and non-blinded studies were in-
cluded. We excluded case reports and case series with small
patient numbers (n < 5), review articles without original data,
editorials, letters, and conference papers. All studies included
in the systematic review were eligible for the study-aggregate
meta-analysis, with exception for those with unacceptable risk
of bias (e.g. no valid reference test) and/or patient overlap.
Two researchers (DtH and GT) independently reviewed titles
and abstracts of the retrieved articles, applying the inclusion
and exclusion criteria mentioned above. The full text of the
remaining articles was examined to assess their eligibility for
inclus ion in the s tudy-aggregate meta-analys is .
Disagreements were resolved in a consensus meeting with a
third reviewer (AG).
Data extraction and quality assessment
QUADAS-2 [13] was used to systematically assess the risk of
bias and applicability concerns for all included studies. The
criteria considered by QUADAS-2 are selection bias, index
test bias, reference test bias, and flow-and-timing bias.
Selection bias risk was considered high if there were unex-
plained exclusions in the study and considered unknownwhen
selection criteria were not (fully) described. FDG-PET/CT
was considered to be the index test. Bias risk for the FDG-
PET/CT scan was deemed low if the imaging specialists were
blinded to the results of other diagnostic modalities and the
final diagnosis of patients and if the scan was performed ac-
cording to EANM/EARL procedural guidelines [14–16]
These entail patient preparation with a low-carbohydrate, fat
allowed diet and a period of fasting before the scan of at least
6 h and analysis of both attenuation corrected and uncorrected
PET images. If assessors were not blinded and EARL/EANM
procedural guidelines were not followed, the risk of bias was
considered high. All studies in between, with either EARL/
EANM recommendations not followed or with non-blinded
assessors, were considered intermediate/unknown risk.
Because the multidisciplinary consensus criteria according to
the International Society of Heart and Lung transplantation
(ISHLT) [17] do not constitute a true gold standard, but are
currently the best known alternative, bias risk for reference
test was considered intermediate for all studies that adhered
to these criteria for the diagnosis. Those that deviated from
ISHLT criteria were considered high risk. For flow and
timing, assessment of bias risk was complicated by the fact
that the ‘adequate’ time interval between index test and refer-
ence test is unknown (e.g. optimal duration of follow-up).
Additionally, and in particular in the situation where patients
were already treated with antibiotics at the time of FDG-PET/
CT, the duration of antibiotic use may influence the value of
the scan for the diagnosis, but its exact impact is unknown.
Therefore, all studies were considered ‘unknown risk’ for this
domain.
Reference standard of diagnosis
For classification of the diagnosis of both driveline infec-
tions and infections of the central LVAD components
(pump housing, outflow tract, and pump pocket for earlier
LVAD generations, e.g. Heartmate II), we adhered to di-
agnostic criteria proposed in the 2011 consensus state-
ment by the ISHLT [17] and the similar adverse event
defini t ion of device specif ic major infect ion of
INTERMACS [18]. Accordingly, it was verified for all
studies whether they included findings of all clinical in-
vestigations, including cultures/swabs, trans-oesophageal
echocardiography, CTA if available, clinical course, and
follow-up. Because of the diagnostic challenge LVAD
infections may present, it was also checked whether the
final diagnosis was made by a specialized multidisciplin-
ary team, consisting of cardiologists, thoracic surgeons,
infectious disease specialists, medical microbiologists,
and imaging specialists, with access to all relevant clinical
information in case there was any doubt about the clinical
diagnosis.
Statistical analysis
Statistical analyses were performed using Open Meta-Analyst
(BROWN School of Public Health, Providence, RI, USA).
Pooled subgroup analyses were performed for all included
studies that evaluated FDG-PET/CT for its diagnostic value
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in establishing or ruling out driveline infections and/or infec-
tions of LVAD pump/pocket. Since two of the included stud-
ies only focused on FDG-PET/CT assessment of the driveline
[19, 20] apart from the overall analysis of FDG-PET/CT ac-
curacy, additional analyses were performed for driveline and
central device components separately. Bivariate analysis of
sensitivity and specificity was performed using likelihood ra-
tio estimates with 95% confidence intervals (CI). An I2 higher
than 50% was considered indicative of significant study het-
erogeneity [21]. Negative and positive likelihood ratios, as
well as diagnostic odds ratios (DOR), were calculated.
Negative and positive predictive values and the diagnostic
accuracy were not considered as accurate since the prevalence
of LVAD and/or driveline infections in the patient population
of interest is unknown, violating an assumption for NPV,
PPV, and diagnostic accuracy calculations. The values of neg-
ative likelihood ratio (NLR) and positive likelihood ratio
(PLR) indicate to what extent the probability of having a dis-
ease decreases given a negative test result and how much the
probability of the disease increases, given a positive test, re-
spectively. The diagnostic odds ratio indicates how the prob-
ability of a correct diagnosis changes after performing the test
(with a higher value indicating better performance).
Results
Selection of literature
A total of 71 articles were identified through an electronic
database search (Fig. 1). After removing one duplicate, the
remaining 70 articles were screened based on title and/or ab-
stract. Fifty-nine studies were excluded because they either
had a different focus than the research question, presented
no original data, or lacked a full text. Eleven studies were
deemed eligible for full-text analysis. Cross-checking refer-
ences for any additional publications yielded no extra results.
One of the articles was excluded from further analysis because
it contained insufficient data specific to our research question
(only two patients in the study population had an LVAD) [22].
In total, 10 studies (n = 382 scans in 318 patients) were includ-
ed in the systematic review. Two of the studies that were
included in the systematic review were excluded from the
meta-analysis: one because of suspected data overlap with a
later study published by the same author [23, 24], the other
because of methodology/applicability concerns based on full-
text analysis [24]. The latter study included analyses of FDG-
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Research question: Diagnostic performance of FDG-PET/CT in patients suspected of LVAD infection
Research string: (Left ventricular assist device[tiab] OR LVAD[tiab] OR Ventricular Assist Device[tiab] OR VAD[tiab]) And
(infection[tiab] OR endocarditis[tiab] or Endocarditis[mesh]) AND (Positron emission tomography[tiab] OR PET) NOT 
(case report[tiab])
Full-text articles excluded from quantitative synthesis
(n=2):
Suspected data overlap (n=1)
Methodology/applicability concerns (n=1)
Full-text excluded (n=1)
Insufficient data on research question for analysis
Records found through 
cross references (n=0)
Duplicates removed (n=1)
Fig. 1 Research question: Diagnostic performance of FDG-PET/CT in
patients suspected of LVAD infection Research string:(left ventricular
assist device[tiab] OR LVAD[tiab] OR ventricular assist device[tiab]
OR VAD[tiab]) And (infection[tiab] OR endocarditis[tiab] or
endocarditis[mesh]) AND (positron emission tomography[tiab] OR
PET) NOT (case report[tiab])
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on driveline exit site swabs only, which cannot be used as a
standalone reference test for any deeper infection of the drive-
line or central device components. Furthermore, this study
included only patients with a relatively late stage of infection,
leading to selection bias and applicability concerns. Therefore,
for the meta-analysis, eight studies (n = 256 scans in 230 pa-
tients) were found eligible.
Systematic review: study characteristics
In the ten articles included in the systematic review, a total of
382 FDG-PET/CT scans were acquired for 318 patients. A
suspicion of LVAD-related infection was the reason for
performing the FDG-PET/CT in 232 scans, 6 of which were
for evaluation of treatment, while all others were considered
separate episodes. The remaining 150 scans were either part of
work-up for heart transplantation or assessment of pathology
unrelated to LVAD (e.g. malignancy). In 78 scans, only the
driveline was evaluated [19, 20]. One publication had a pro-
spective study design [25], while all others used retrospective
patient data. Median age of participants ranged from 52 to
64 years. The study population was predominantly male, pro-
portions ranging from 77.8 to 90.5%. The characteristics of
the ten included studies are summarized in Table 1.
Technical aspects
In all studies, FDG-PET scans were performed on a hybrid
PET/CT system, combining an FDG-PET scan with a low-
dose CT for anatomical reference and attenuation correc-
tion. In one study, the FDG-PET scan was combined with
diagnostic CTA [27]. Reporting of injected activity dif-
fered between studies: while some reported an injected
activity per kilogram of body weight, others reported a
mean total injected activity with lower and upper ranges.
The injected activity was also highly variable for included
studies, ranging from 215 to 474 MBq for the mean total
activity and 2.3 to 5 MBq per kg body weight (EANM
guidelines advice: 2.5–5.0 MBq/kg [15]). According to
study protocols, all scans were performed approximately
60 min after injection of FDG. However, the actual time
intervals in clinical practice were not reported.
Visual analysis of the scans was performed in all studies;
in 5 studies, this was combined with semi-quantitative anal-
yses, using SUVmax [19, 20, 24] and target-to-background
ratios (TBR) [23, 24, 28], reference regions being lung pa-
renchyma and deltoid muscle [23, 28], or thoracic aorta and
liver [24]. In one study, metabolic volume was also used:
this was defined as the measured volume of a target lesion
Table 1 Study and patient characteristics
Authors Year Country Study
design













2018 Netherlands R Suspected device-related infection 10 (9) 54 77.8% 8/10
Avramovic
et al. [19]
2017 Germany R Suspected device-related infection (focus of study:
driveline) or PET/CT as part of work-up for heart
transplantation
48 (48) 57 83.3% 24/48
Bernhardt
et al. [27]
2017 Germany R Suspected device-related infection 29 (21) 54 90.5% 16/29
Dell’ Aquila
et al. [28]
2016 Germany R Suspected device-related infection 40 (31) 52 78.1% 30/40
Dell’ Aquila
et al. [23]





2019 France R Suspected device-related infection 24 (22) 57 87.5% 21/24
Kanapinn
et al. [20]
2019 Germany R Suspected device-related infection (all had baseline
scan before: focus of study: driveline)
30 (30) 54 86.7% 23/30
Kim et al.
[25]
2019 USA P Suspected device-related infection. Controls: base-
line PET/CT




2019 Germany R Device-related infection, evaluation of extent of
infection
85 (57) 56 86.0% 85/85
Tam et al.
[30]
2019 USA R Suspected device-related infection 19 (18) 61 78.9% 17/19
FDG fluorine-18 fluorodeoxyglucose, LVAD left ventricular assist device, P prospective, PET/CT positron emission tomography/computed tomogra-
phy, R retrospective
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showing more FDG uptake than the mean FDG uptake in a
delineated region of interest in the liver plus 2.5 standard
deviations, with a minimum volume of 9 cm3 [19]. The
technical details of the included studies are summarized in
Table 2.
Methodological quality of included studies
The QUADAS-2 risk of bias of all studies evaluated for meta-
analysis eligibility is summarized in Fig. 2. Two studies had a
high risk of bias for patient selection, one due to unexplained
patient exclusions [25], the other because of a case series of
patients with late-stage infections [24]. All other studies de-
scribed a suspicion of device-related infection as inclusion cri-
terion, but this suspicion was not further elaborated or defined.
Therefore, all other studies were considered to have an un-
known risk for patient selection bias. Only one study had a
low risk of bias for the index test, having assessors of the
FDG-PET/CT blinded to findings of other clinical tests and
final diagnosis for patients, while also performing the FDG-
PET/CT scan according to EANM recommendations with a
high-fat, low carbohydrate diet, a pre-scan fast of more than
6 h, and assessment of both attenuation-corrected and
attenuation-uncorrected images [25]. In other studies, observers
were either not blinded to clinical context of patients or assess-
ment of non-attenuation-corrected images was not described.
Two studies performed the reference test fully in accordance
with ISHLT recommendations [27, 29]. Two studies had high
applicability concerns for both index test and reference test,
because they focused on the LVAD driveline only [19, 20].
Impact on prognosis and patient management
The ability of FDG-PET/CT to predict outcome and help inform
management of device infections was discussed in three of the
articles included in the systematic review [24, 25, 27]. In one
Table 2 Technical aspects of 18F-FDG PET/CT studies included in systematic review
First author, year Imaging modality Mean injected





Image analysis Comparison to
other imaging
modalities
Akin et al. 2018
[26]
PET/CT(low-dose CT) 2.3 MBq/kg
μtot = NR
60 min. Visual analysis None
Avramovic et al.
2017 [19]
PET/CT, (low-dose CT) 5 MBq/kg
μtot = 338 MBq
60 min. Visual + semi-quantitative







μtot = 351 MBq




PET/CT(low-dose CT) 5 MBq/kg
μtot = 308 MBq







PET/CT(low-dose CT) 5 MBq/kg
μtot = 344 MBq







PET/CT(low-dose CT) 3.5 MBq/kg
μtot = 310 MBq
60 min. Visual analysis WBC-SPECT
Kanapinn et al.
2019 [20]
PET/CT(low-dose CT) MBq/kg NR
μtot = 215 MBq
(1st scan)
μtot = 218 MBq
(2nd scan)




Kim et al. 2019
[25]
PET/CT(low-dose CT) MBq/kg NR
μtot = 474 MBq




PET/CT(low-dose CT) MBq/kg NR
μtot = NR, range
198–326 MBq
60 min. Visual + semi-quantitative
analysis (SUVmax, TBR)
None
Tam et al. 2019
[30]
PET/CT(low-dose CT) MBq/kg NR
μtot = NR, range
333–370 MBq
60 min. Visual analysis None
FDG fluorine-18 fluorodeoxyglucose, INTERMACS Interagency Registry forMechanical Circulatory Support, LVAD left ventricular assist device,MBq
MegaBecquerel, min. minutes, μtot mean total injected activity, MV metabolic volume, NR not reported, PET/CT positron emission tomography/
computed tomography, SUVmax maximal standardized uptake value, SUVmean mean standardized uptake value, TBR target-to-background ratio,
WBC-SPECT white blood cell single photon emission computed tomography
1According to study protocol; actual values during study not reported
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study, a positive FDG-PET/CT was associated with a 50% mor-
tality during follow-up (median survival 87.5 days), which
contrasted with the non-infected group, in which no patients died
during follow-up (median follow-up duration of 165 days).
Twelve out of the 14 (86%) patients who died had involvement
of pump or pocket infection [25]. In another study, FDG-PET/
CT helped clinicians change their medical strategy for 12 out of
21 patients (57%), including four patients that were listed for
high urgency heart transplantation based on FDG-PET/CT re-
sults. In all these cases, infection of the LVADdevice or the deep
driveline was confirmed at transplantation. [27]. In the third
study, an association was found between FDG uptake of thoracic
lymph nodes and adverse outcome, although this was not found
for increased FDG uptake along the driveline or around any
central LVAD device component [24].
Meta-analysis: pooled diagnostic performance
In the eight articles included in the study-aggregate meta-anal-
ysis, a total of 256 FDG-PET/CT scans were acquired in 230
patients. A suspicion of device-related infection was the rea-
son for performing FDG-PET/CT in 232 scans. In 78 scans,
only the driveline was evaluated [19, 20].
For the assessment of overall device-related infections,
pooled sensitivity and specificity of FDG-PET/CT were 0.95
(95% CI 0.89–0.97) and 0.91 (95% CI 0.54–0.99) respective-
ly. NLRwas 0.14 and positive likelihood ratio, PLR, was 3.54
with an overall DOR of 38.43.When only assessing the drive-
line, FDG-PET/CT pooled sensitivity, specificity, NLR, PLR,
andDORwere respectively 0.97 (95%CI 0.88–0.99) and 0.99
(95% CI 0.13–1.0, 0.13, 3.93, and 92.46. When only
assessing pump/pocket infections, FDG-PET/CT pooled sen-
sitivity and specificity were 0.97 (95% CI 0.70–1.0) and 0.93
(95%CI 0.64–0.99) respectively. NLRwas 0.12 and PLRwas
5.56 with an overall DOR of 49.43.
The I2 test for heterogeneity was positive (> 50%) for PLR
of FDG-PET/CT, for assessment of driveline only, pump/
pocket only, and the combination of both. Results of the
meta-analysis for LVAD-specific infections, in which find-
ings for pump/pockets and driveline are combined, are
Legend: Green = Low risk, Yellow = Unknown/Intermediate risk, Red = High risk, Black = Reason for exclusion 
meta-analysis. *Dell’ Aquila et al.’s 2016 study was excluded because of suspected data overlap with their 2018 
study. 
Fig. 2 QUADAS-2 risk assessment
Eur J Nucl Med Mol Imaging
summarized in Table 3 and Fig. 3. The split analyses of drive-
line and pump/pocket infections are shown as ROC curves in
Fig. 4. The corresponding tables and forest plots can be found
under supplemental data: Tables 4 and 5, Figs. 6 and 7. Plots
for FDG-PET/CT diagnostic odds ratios are represented in
supplemental data Figs. 8–10.
While 5 studies mentioned the use of semi-quantitative
analysis [19, 20, 23, 24, 28], only 3 of these described its
findings in comparison with visual analysis. Visual analysis
outperformed semi-quantitative analysis in 2 studies [23, 28]
while in one study [19], both semi-quantitative analyses using
SUVmax and especially metabolic volume with a cutoff of >
9 cm3 outperformed visual analysis, with 2/3 false negatives
and 2/5 false positives correctly classified using metabolic
volume.
In one study, all patients underwent two scans: a baseline
scan without suspicion of infection, and a second one for
assessment of driveline infection [20]. The baseline scan
may have facilitated the interpretation of the second diagnos-
tic scan, which might explain the absence of any false posi-
tives or false negatives in this study, although this warrants
validation in further studies.
Table 3 Overall diagnostic performance of FDG-PET/CT in patients with suspected LVAD and/or driveline infection
Authors,
year










Sensitivity Specificity PLR NLR
Akin et al.
2018 [26]
Clinical course review by research group including
medical history, comorbidities, cultures of blood and
driveline (sternal wound if suspect), laboratory tests,
imaging results, and outcome at end of recorded
follow-up. Diagnosis according to INTERMACS
definition of LVAD infection.




Clinical course review at the end of recorded follow-up or
transplantation: clinical evidence of infection or recur-
rence of symptoms, swabs at driveline exit, along
driveline, surgical samples if available, and laboratory






















ISHLT criteria at end of follow-up, based on clinical
symptoms, cultures, and swabs of exit site, along
driveline and during surgery if available, and imaging
data. In case of missing data, consensus diagnosis
made during multidisciplinary meeting.




Findings of MMB (cultures of skin and/or tissue sur-
rounding driveline or central device components if
available), surgery, clinical evidence of infection, and
recurrence of symptoms at end of recorded follow-up,
diagnosis according to INTERMACS definition of
LVAD infection.




Clinical evidence of infection, cultures of skin and/or
tissue surrounding driveline or central device compo-
nents if available), surgery, and recurrence of symp-
toms at end of recorded follow-up. Diagnosis accord-
ing to INTERMACS definition of LVAD infection.





ISHLT criteria at end of follow-up, based on clinical
symptoms, microbiology, and imaging data. In case of
missing data, consensus diagnosis made during
multidisciplinary meeting.




Consensus by 2 physicians with access to clinical criteria,
findings of MMB (not further defined), and all
diagnostic imaging (incl. FDG-PET/CT).
23 0 0 7 1.0 1.0 ∞ 0.00
Kim et al.
2019 [25]
Findings ofMMB, surgery, clinical evidence of infection,
and recurrence of symptoms; it was not reported who
performed the reference test.





Clinician determined presence or absence of LVAD
infection based on history, laboratory tests, imaging
studies, and clinical outcome. Confirmation at 30 day
follow-up.
11 0 6 2 1.0 0.250 1.33 0.00
FDG fluorine-18 fluorodeoxyglucose, INTERMACS Interagency Registry forMechanical Circulatory Support, ISHLT International Society of Heart and
Lung Transplantation, LVAD left ventricular assist device,MMBmedical microbiology,MVmetabolic volume, PET/CT positron emission tomography/
computed tomography
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Analysis of false positive and false negative scans was
performed in 4 studies [23, 27, 29, 30]. In one study, the cause
of 2 false negatives could not be established [24]. In another, it
is implied that the reason for their single false negative result
might have been the 30-day period of antibiotic treatment at
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Overall (I^2=58.34 % , P=0.019)
Estimate (95% C.I.) 
5.667 (0.449,  71.512)
4.200 (1.898,   9.295)
23.882 (1.559, 365.823)
3.150 (1.589,   6.243)
2.857 (0.575,  14.196)
15.667 (1.069, 229.513)
15.724 (1.074, 230.309)
1.327 (0.870,   2.024)
3.539 (1.826,   6.859)










0.45 0.9 2.25 3.54 8.98 22.45 44.9 89.81 224.52 365.82
Positive Likelihood Ratio (log scale)
Positive Likelihood Ratio Overall PLR: 3.539
Overall NLR: 0,136
Fig. 3 NLR and PLR forest plots for FDG-PET/CT for LVAD-specific infections (pooled analysis of driveline and LVAD)
Fig. 4 ROC curves for FDG-PET/CT for LVAD-specific infections
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positives, 4 patients had concurrent bacteraemia or other pos-
sible sources of infection, 1 patient had increased cardiac sar-
coidosis activity, and 1 had a newly diagnosed chronic mye-
loid leukaemia. The exact effect of these comorbidities on
FDG-PET/CT results in their study remained unclear. The
most extensive analysis of false positives and false negatives
was performed by Dell’ Aquila et al. [23]. They described
prolonged antibiotic use, infection limited to the pump hous-
ing as the causes for false negatives, and the presence of
chronic fistulas as main causes for a false positives in 3 cases,
whereas 7 other cases remained unexplained.
Analyses of scans performed shortly after LVAD implan-
tation showed robustness of the scan in this setting: in one
study, a true negative was reported 3 weeks after LVAD im-
plantation [26] and in another, 5 true positives and 5 true
negatives were reported within 3 months after LVAD implan-
tation [23].
Discussion
We have pooled the data on the diagnostic value of
FDG-PET/CT in detecting pump/pocket and driveline
infections in patients with a LVAD to obtain more ro-
bust estimates of diagnostic performance of FDG-PET/
CT in this setting. FDG-PET/CT is already included in
guidelines for endocarditis and cardiovascular implant-
able electronic devices. Supporting evidence is emerging
for the use of FDG-PET/CT in device-related infection
in patients with LVADs. However, most of the reported
studies have limited power, due to relatively small pa-
tient numbers enrolled and different acquisition and in-
terpretation criteria. The separate evaluation of FDG-
PET/CT accuracy for infections of LVAD pump/pocket
and the driveline, next to the analysis in which these
were combined, allowed us to include a significant
amount of studies and patients to the analyses. In addi-
tion, we performed a further in-depth analysis of the
included studies’ methodology and a stratification for
driveline versus central device components, with recom-
mendations for future studies. We performed no separate
analyses for white blood cell (WBC) scintigraphy. Its
diagnostic value was evaluated by only one study [29],
making any pooling of data impossible beforehand.
Summarily, in this study, FDG-PET/CT was found to
have higher sensitivity (95.2 vs 71.9, p = 0.01), while
a difference in specificity favouring WBC scintigraphy
was not found to be statistically significant (66.7 vs
100, p = 0.32), although the study was underpowered
to detect such a difference with only 3 negative cases.
To our opinion, while potentially useful as a high spec-
ificity test in situations where FDG-PET/CT results are
unclear, evidence for WBC scintigraphy so far is insuf-
ficient to make any recommendations in that regard.
Clinical value of FDG-PET/CT in suspicion of LVAD-
related infections
Considering the value of FDG-PET/CT in LVAD-related in-
fections, we found a high overall sensitivity and specificity
(both above 90%), underscoring its value in clinical practice.
It was also found to have impact on prognosis and patient
management. This is particularly important because of the
severity of these infections and the difficulty of both their
diagnosis and treatment. Accurate information about the pres-
ence and extent of an infectious process is of great importance
for determining appropriate treatment e.g. duration of antibi-
otic treatment and/or extent of surgical debridement, while
follow-up scans may be used to evaluate treatment response.
Heterogeneity and technical considerations of FDG-
PET/CT
Although the overall accuracy of FDG-PET/CT for the diag-
nosis of device-related infection was excellent, we also found
significant heterogeneity amongst studies. The current lack of
a standardized FDG-PET/CT procedure, such as the wide va-
riety of injected activity, the possibly variable intervals be-
tween injection of the FDG and the subsequent scan, the var-
iable use of a low carbohydrate, fat allowed diet prior to FDG-
PET/CT, and missing analysis of non-attenuation-corrected
PET images along with the attenuation-corrected images,
may well explain the wide confidence intervals that were
found for specificity of the test and the corresponding hetero-
geneous positive likelihood ratio. If the low carbohydrate, fat
allowed diet is not used, there is a substantial risk of physio-
logical myocardial uptake [31]. This may render any assess-
ment of the pump housing impossible. The use of non-
attenuation-corrected FDG-PET/CT images to confirm in-
creased uptake surrounding the device is important, because
the attenuation correction for the FDG-PET is based on the CT
images, which means beam hardening artefacts are incorpo-
rated in the calculated FDG uptake, leading to distortions [32].
Further standardization of FDG-PET/CT protocols using the
EARL criteria, applying a strict protocol for patient prepara-
tion, and providing robust interpretation criteria could sub-
stantially reduce heterogeneity caused by such confounders
and increase consistency of the high overall specificity. The
findings of scans performed shortly after LVAD implantation
suggest that reactive inflammation after LVAD implantation
may be relatively short, making FDG-PET/CT feasible early
after surgery, possibly as soon as 1 month after device implan-
tation and almost certainly 3 months after LVAD
implantation.
Eur J Nucl Med Mol Imaging
Studies comparing visual analysis with semi-quantitative
analysis found conflicting results onwhich of these is the most
accurate during assessment of pump/pocket infections or
driveline infections. Using both is probably the best approach
in clinical practice until more evidence is gathered for prefer-
ring one method over the other. A clear limitation of semi-
quantitative analysis is that cutoff values are not necessarily
interchangeable between different PET/CT systems. This can
be circumvented by calibrating the PET/CT system according
to EARL or using either metabolic volume or reference re-
gions to determine increased FDG avidity surrounding the
device or driveline.
Inclusion criteria for all studies investigated were a clinical
suspicion of driveline infection or infection of central LVAD
components with or without a control group. However, no
clearly defined criteria exist to establish a suspicion of
device-related infection, which introduces a risk of selection
bias e.g. overestimation of FDG-PET/CT accuracy if only
performed in late-stage infection and underestimation of
FDG-PET/CT accuracy if performed for incidental findings
on echocardiography in spite of absent clinical signs of infec-
tion. Detailed description of the clinical presentation for all
included patients can partially mitigate this risk, but to elimi-
nate it entirely, predefined criteria for suspicion are needed.
Proposal for structured approach in suspicion of
LVAD-related infection, including FDG/PET-CT
To eliminate selection bias, we propose to distinguish between
pump/pocket and driveline infection, as both their assessment
and clinical significance differs. Central infections would in-
clude infections of the pump pocket, and outflow tract, and,
for older LVAD generations such as Heartmate II, the pump
pocket. For the driveline infections, signs like localized pain
and erythema with or without purulent discharge at the drive-
line exit site would lead to a suspicion of infection. For infec-
tion of pump or pocket, criteria could be derived from the
guidelines aimed at standardizing the suspicion for infective
endocarditis, as published by the BSAC [33], with adjust-
ments for this specific patient group. Therefore, we propose
the following criteria for suspecting an infection of central
LVAD components; see Fig. 5. If infection of LVAD pump/
pocket is suspected, FDG-PET/CT would be indicated either
for establishing the diagnosis, for determining the extent of
infection, or for assessing dissemination to other organs.
Limitations
When assessing the diagnostic accuracy of any test for estab-
lishing device-specific infections in patients with an LVAD, a
fundamental difficulty is the absence of a gold standard, due to
associated risk of surgery and the inability of conventional
investigations to accurately determine the extent of infection.
Furthermore, the included studies were all relatively small and
with significant differences in study protocols, leading to large
heterogeneity. We took these factors into account to provide
the most comprehensive review of the evidence so far.
The included studies focused almost exclusively on contin-
uous flow LVAD systems. While this might limit the gener-
alization of the results, these devices represent the vast major-
ity of modern ventricular assist devices. Moreover, although
the devices were almost exclusively LVADs, they were not all
of the same type and/or generation, and it is certainly possible
that LVADs made by different manufacturers and different
materials may show different physiological uptake, impacting
FDG-PET/CT accuracy. Furthermore, a difficult implantation
of the device may cause a prolonged inflammatory response,
impairing test accuracy, but there are currently no FDG-PET/
CT data available on the impact of these factors for clinical
practice.
Conclusion
Our systematic review and meta-analysis demonstrates that
FDG-PET/CT is a valuable tool for establishing or excluding
the diagnosis of device specific infection in patients with a left
ventricular assist device, with a high sensitivity and a high,
albeit variable, specificity. Future studies, in which criteria for
suspecting device infection and scan procedures are standard-
ized, are needed to confirm that this will lead to consistently
high specificity and to further elucidate the role of semi-
quantitative analyses that can be used across different PET/
1. Fever without obvious alternative diagnosis 
2. Fever with one of the following:
a. a recent procedure associated with bacteraemia
b. Signs of device dysfunction/thrombosis
c. Vascular or immunological phenomena 
d. New cerebrovascular event
e. Peripheral abscesses 
f. Signs of driveline infection (e.g. purulence, pain, erythema)
g. Signs of sternal wound infection (e.g. purulence, pain, erythema) 
3. Prolonged period of night sweats, unintended weight loss, anorexia or malaise
4. Unexplained, persistently positive blood cultures 
5. Intravascular catheter related bacteraemia with positive blood cultures 72h after removal 
Fig. 5 Proposed clinical signs/
symptoms warranting suspicion
of infection of central LVAD
components
Eur J Nucl Med Mol Imaging
CT systems. Despite these limitations, the current evidence
strongly supports implementation of FDG-PET/CT in the
standard work-up of patients with suspected LVAD-related
infections, in particular when initial clinical investigations
are inconclusive.
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